Improved airway targeting with the CFC-free HFA-beclomethasone metered- dose inhaler compared with CFC-beclomethasone

European Respiratory Journal

Volumn 12, Issue 6, 1998, Pages 1346-1353

  Leach, C L ^a   Davidson, P J ^a   Boudreau, R J ^b  

^a 3M COMPANY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Asthma; Beclomethasone; Lung deposition

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; FLUORINATED HYDROCARBON; TECHNETIUM 99M;

ADULT; AIRWAY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; METERED DOSE INHALER; OROPHARYNX; PARTICLE SIZE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AEROSOL PROPELLANTS; ASTHMA; BETAMETHASONE; CHLOROFLUOROCARBONS; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCARBONS, FLUORINATED; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; OROPHARYNX;

EID: 0032438394     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12061346     Document Type: Article

References (32)

1. United Nations Environmental Programme (Ozone Secretariat). Handbook for the International Treaties for the Protection of the Ozone Layer, 4th Edn. Kenya, 1996.
2. US Food and Drug Administration. Advance notice of proposed rulemaking on chlorofluorocarbon propellants in self-pressurized containers; determinations that uses are no longer essential. 62 Fed. Reg. 10242, March 6, 1997.
3. Hayman G. Why the environment matters. Br J Clin Pract 1995; Suppl. 79: 2-6.
4. Leach CL. Preclinical safety of propellant HFA-134a and Airomir. Br J Clin Pract 1995; Suppl. 79: 10-12.
5. Alexander DJ. Safety of propellants. J Aerosol Med 1995; 8: S29-S47.
6. Leach CL. Safety Assessment of the HFA propellant and the new inhaler. Eur Respir Rev 1997; 7: 35-36.
7. Holgate ST. Asthma: past, present and future. Eur Respir Rev 1993; 6: 1507-1520.
8. Leach CL. Enhanced drug delivery through reformulating MDIs with HFA propellants - drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory Drug Delivery V Proceedings. Buffalo Grove, Interpharm Press, 1996; pp. 133-144.
9. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-875.
10. Conway JH, Holgate ST. Targeting therapy to inflamed airways in asthma. J Aerosol Med 1994; 7: 161-165.
11. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505-1510.
12. Adcock IM, Gilbey T, Gelder CM, Chung KF, Barnes PJ. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996; 154: 771-782.
13. Newman SP. Scintigraphic assessment of therapeutic aerosols. Crit Rev Ther Drug Carrier Sys 1993; 10: 65-109.
14. 99mTc labelled particles for aerosol studies. Radiochem Radioanal Lett 1970; 5: 275-277.
15. Köhler D, Fleischer W, Matthys H. New method for easy labelling of beta-2 agonists in the metered dose inhaler with Tc99m. Respiration 1988; 53: 65-73.
16. Newman SP, Pavia D, Moren F, Sheahan NF, Clarke SW. Deposition of pressurized aerosols in the human respiratory tract. Thorax 1981; 36: 52-55.
17. Snedecor GW, Cochran WG. Statistical methods. 7th Edn. Ames, Iowa State University Press, 1980.
18. Newman SP, Moren F, Pavia D, Little F, Clarke SW. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis 1981; 124: 317-320.
19. O'Reilly JF, Gould G, Kendrick AH, Laszlo G. Domiciliary comparison of terbutaline treatment by metered dose inhaler with and without conical spacer in severe and moderately severe chronic asthma. Thorax 1986; 41: 766-770.
20. Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1966; 9: 55-70.
21. Dolovich M. Measurement of particle size characteristics of metered dose inhaler (MDI) aerosols. J Aerosol Med 1991; 4: 251-263.
22. Task Group on Lung Dynamics. Deposition and retention models for internal dosimetry of the human respiratory tract. Health Physics 1966; 12: 173-207.
23. Stahlhofen W, Rudolf G, James AC. Intercomparison of experimental regional aerosol deposition data. J Aerosol Med 1989; 2: 285-308.
24. Rudolf G, Kobrich K, Stahlhofen W. Modeling and algebraic formulation of regional aerosol deposition in man. J Aerosol Sci 1990; 21: S403-S406.
25. Harrison LI, Dahl DR, Cline A, et al. Pharmacokinetics and dose proportionality of beclomethasone from three strengths of a CFC-free beclomethasone dipropionate metered-dose inhaler. Biopharm Drug Dispos 1997; 18: 635-643.
26. Gross G, VandenBurgt J, Donnell D, Amies M, Stampone P. New formulation inhaled steroid achieves equivalent peak flow control with half the daily dose in moderate asthmatics (Abstract). Eur Respir J 1996; 9: Suppl. 23, 255s.
27. Davies R, Simmons J, Stampone P, Donnell D. Equivalent asthma symptom control of 1500 μg beclomethasone dipropionate (BDP) achieved with 800 μg BDP from fine aerosol solution (Abstract). Eur Respir J 1996; 9: Suppl. 23, 254s.
28. Kunkel G, Novak D, Kristufek P, et al. A multinational study assessing the efficacy and safety of a CFC-free pMDI (Abstract). Eur Respir J 1996; 9: Suppl. 23, 254s.
29. Hammermaier A, Bidlingmaier A, Waitzinger J, Stechert R, Wenske H, Jaeger H. Radiolabelling of drugs in a metered dose inhaler (MDI) and lung deposition in human subjects. J Aerosol Med 1994; 2: 173-176.
30. Newman SP, Moren F, Trofast E, Talaee N, Clarke SW. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multidose powder inhaler. Eur Respir J 1989; 2: 247-252.
31. Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler™: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994; 7: 69-73.
32. Biddescombe, MF, Melchor R, Mak VHF, et al. The lung deposition of salbutamol, directly labelled with technetium-99m, delivered by pressurized metered dose and dry powder inhalers. Int J Pharm 1993; 91: 111-121.